

---

*Montana*

TUBERCULOSIS  
PROGRAM MANUAL



# Table of Contents

---

<b>INTRODUCTION</b>	
<b>About the <i>Montana Tuberculosis Program Manual</i></b>	<b>1.2</b>
Purpose.....	1.2
Audience.....	1.2
<b>How to Use This Manual</b>	<b>1.3</b>
Portable document format.....	1.3
Hyperlinks .....	1.3
Cross-references .....	1.3
Forms.....	1.3
Bookmarks and display size .....	1.4
Printing.....	1.5
Icons .....	1.6
Abbreviations .....	1.7
<b>Purpose of Tuberculosis Control.....</b>	<b>1.10</b>
<b>Montana Laws and Rules on Tuberculosis Control.....</b>	<b>1.11</b>
<b>Montana and National Objectives .....</b>	<b>1.12</b>
Montana Tuberculosis Program objectives—2009 .....	1.12
National program objectives .....	1.13
Standards .....	1.15
Montana evaluation plan 2006–2007.....	1.16
<b>Roles, Responsibilities, and Contact Information .....</b>	<b>1.17</b>
Montana Tuberculosis Program staff.....	1.17
Local public health agencies and private medical providers .....	1.18
State laboratory.....	1.19
<b>Resources and References .....</b>	<b>1.20</b>
<b>SURVEILLANCE</b>	
<b>Introduction .....</b>	<b>2.2</b>
Purpose .....	2.2
Policy.....	2.5
Laws and rules .....	2.5
<b>Reporting Tuberculosis .....</b>	<b>2.6</b>
Reporting suspected or confirmed cases of tuberculosis to the local public health agency .....	2.8
Required reports from local public health agencies to the Montana Tuberculosis Program.....	2.10
<b>Data Collection Forms.....</b>	<b>2.11</b>
<b>Genotyping .....</b>	<b>2.12</b>
<b>References.....</b>	<b>2.14</b>
<b>TARGETED TESTING FOR LATENT TUBERCULOSIS INFECTION</b>	
<b>Introduction .....</b>	<b>3.2</b>
Purpose .....	3.2
Policy.....	3.2
<b>High-Risk Groups .....</b>	<b>3.3</b>
<b>When to Conduct Targeted Testing .....</b>	<b>3.5</b>
Approaches to increasing targeted testing and treatment for latent tuberculosis infection.....	3.5
Screening for latent tuberculosis infection in facilities.....	3.6
<b>References.....</b>	<b>3.7</b>

## B NOTIFICATIONS

<b>Introduction.....</b>	<b>4.2</b>
Purpose.....	4.2
Policy .....	4.5
<b>Follow-up of B1 and B2 Tuberculosis Arrivals.....</b>	<b>4.6</b>
Division of Global Migration and Quarantine forms.....	4.6
Patient follow-up .....	4.6
<b>Evaluation of B1 and B2 Tuberculosis Arrivals.....</b>	<b>4.8</b>
Evaluation activities .....	4.8
Treatment.....	4.9
<b>Resources and References .....</b>	<b>4.10</b>

## DIAGNOSIS OF TUBERCULOSIS DISEASE

<b>Quick Start Check List .....</b>	<b>5.2</b>
<b>Introduction.....</b>	<b>5.4</b>
Purpose.....	5.4
Policy .....	5.5
Forms.....	5.5
<b>Tuberculosis Classification System.....</b>	<b>5.6</b>
<b>High-Risk Groups .....</b>	<b>5.7</b>
<b>Case Finding .....</b>	<b>5.9</b>
Identifying suspected tuberculosis cases.....	5.9
Follow-up on suspected cases of tuberculosis ..	5.11
<b>Diagnosis of Tuberculosis Disease... </b>	<b>5.12</b>
Medical history .....	5.13
Human immunodeficiency virus screening .....	5.16
Physical examination .....	5.16
Tuberculin skin test and interferon gamma release assays.....	5.16
Chest radiography.....	5.17
Bacteriologic examination .....	5.18
<b>Resources and References .....</b>	<b>5.21</b>

## TREATMENT OF TUBERCULOSIS DISEASE

<b>Quick Start Check List .....</b>	<b>6.2</b>
<b>Introduction .....</b>	<b>6.6</b>
Purpose .....	6.6
Forms .....	6.6
<b>Basic Treatment Principles.....</b>	<b>6.7</b>
<b>Treatment Regimens and Dosages.....</b>	<b>6.9</b>
Regimens .....	6.9
Dosages .....	6.13
Duration of treatment.....	6.16
<b>Side Effects and Adverse Reactions .....</b>	<b>6.18</b>
Basic monitoring steps .....	6.18
Reporting reactions .....	6.20
Monitoring for side effects and adverse reactions by antituberculosis drug.....	6.21
<b>Response to Treatment.....</b>	<b>6.28</b>
<b>Completion of Therapy.....</b>	<b>6.29</b>
<b>Post-Treatment Evaluation .....</b>	<b>6.30</b>
<b>Treatment in Special Situations .....</b>	<b>6.31</b>
Drug-resistant tuberculosis.....	6.31
Human immunodeficiency virus infection.....	6.32
Alcoholism.....	6.33
Liver disease .....	6.34
Renal insufficiency and end-stage renal disease .....	6.34
Tuberculosis associated with tumor necrosis factor-alpha antagonists .....	6.35
Culture-negative pulmonary tuberculosis .....	6.35
Extrapulmonary tuberculosis .....	6.36
Pregnancy and breastfeeding .....	6.37
Tuberculosis in children.....	6.37
<b>Resources and References.....</b>	<b>6.39</b>

<b>DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION</b>	
<b>Quick Start Check List .....</b>	<b>7.2</b>
<b>Introduction.....</b>	<b>7.4</b>
Purpose.....	7.4
Policy .....	7.4
Forms.....	7.4
<b>Tuberculosis Classification System.....</b>	<b>7.5</b>
<b>High-Risk Groups .....</b>	<b>7.6</b>
<b>Diagnosis of Latent Tuberculosis Infection.....</b>	<b>7.8</b>
Mantoux tuberculin skin testing .....	7.8
Candidates for Mantoux tuberculin skin testing .....	7.9
Administration of the tuberculin skin test .....	7.12
Measurement of the tuberculin skin test .....	7.14
Interpretation of the tuberculin skin test.....	7.15
Human immunodeficiency virus screening .....	7.17
Follow-up activities.....	7.17
Chest radiography.....	7.17
<b>Resources and References .....</b>	<b>7.20</b>
Dosages .....	8.12
<b>Side Effects and Adverse Reactions ..</b>	<b>8.13</b>
Basic monitoring steps .....	8.13
Reporting reactions .....	8.15
Monitoring for side effects and adverse reactions by antituberculosis drug.....	8.16
<b>Adherence .....</b>	<b>8.19</b>
Monthly assessment of adherence.....	8.19
Directly observed therapy.....	8.20
<b>Completion of Therapy.....</b>	<b>8.21</b>
<b>Treatment in Special Situations .....</b>	<b>8.23</b>
Human immunodeficiency virus and latent tuberculosis infection.....	8.23
Alcoholism .....	8.24
Pregnancy and breastfeeding .....	8.25
<b>Resources and References.....</b>	<b>8.26</b>
<b>CASE MANAGEMENT</b>	
<b>Quick Start Check List .....</b>	<b>9.2</b>
<b>Introduction .....</b>	<b>9.8</b>
Purpose .....	9.8
Policy .....	9.9
Forms .....	9.9
Acknowledgments .....	9.9
<b>Initial Assessment .....</b>	<b>9.11</b>
Cultural sensitivity and language issues .....	9.11
Patient's medical records .....	9.12
Assessment site .....	9.12
Discharge planning.....	9.12
Initial assessment activities .....	9.12
<b>Treatment Plan .....</b>	<b>9.17</b>
Treatment plan components.....	9.18
Planning activities.....	9.19
Implementation activities .....	9.19

<b>Ongoing Assessment and Monitoring.....</b>	<b>9.22</b>
Ongoing assessment activities .....	9.22
Monitoring side effects and adverse reactions.....	9.26
Monitoring bacteriologic improvement .....	9.27
<b>Completion of Therapy .....</b>	<b>9.30</b>
Verifying adequate course of treatment.....	9.30
Calculating completion of therapy.....	9.30
<b>Evaluation.....</b>	<b>9.32</b>
<b>Directly Observed Therapy .....</b>	<b>9.33</b>
Candidates for directly observed therapy .....	9.33
How to deliver directly observed therapy.....	9.34
Adherence to directly observed therapy .....	9.35
<b>Incentives and Enablers .....</b>	<b>9.38</b>
<b>Legal Orders.....</b>	<b>9.39</b>
<b>Resources and References .....</b>	<b>9.41</b>

## CONTACT INVESTIGATION

<b>Quick Start Check List .....</b>	<b>10.2</b>
<b>Introduction.....</b>	<b>10.6</b>
Purpose.....	10.6
Policy .....	10.7
Forms.....	10.8
<b>Structure of a Contact Investigation .....</b>	<b>10.9</b>
Basic steps of a contact investigation.....	10.9
Contact investigation plan.....	10.9
<b>Decision to Initiate a Contact Investigation .....</b>	<b>10.10</b>
Factors predicting transmission of tuberculosis.....	10.10
Deciding to initiate a contact investigation.....	10.13

## Time Frames for Contact Investigation .....

Information about the index patient and transmission sites.....	10.16
Contact evaluation and treatment .....	10.18
Ongoing management activities.....	10.19
<b>Infectious Period.....</b>	<b>10.21</b>
<b>Index Patient Interviews.....</b>	<b>10.24</b>
Preinterview preparation .....	10.24
General guidelines for interviewing an index patient.....	10.25
<b>Field Investigation .....</b>	<b>10.26</b>
<b>Contact Priorities.....</b>	<b>10.28</b>
Index patient with positive acid-fast bacilli sputum smear results or cavitary tuberculosis.....	10.29
Index patient with negative acid-fast bacilli sputum smear results.....	10.30
Index patient with negative bacteriologic results and abnormal chest radiographs not consistent with tuberculosis.....	10.31

## Contact Evaluation, Treatment, and Follow-up .....

Immunocompromised contacts and children under 5 .....	10.33
Immunocompetent adults and children 5 and older (high- and medium-priority contacts).....	10.35
Contacts with prior positive tuberculin skin tests.....	10.37

## When to Expand a Contact Investigation .....

Guidelines for expanding an investigation.....	10.38
Low-priority contacts .....	10.40

## Data Management and Evaluation of Contact Investigations .....

Reasons contact investigation data are needed .....	10.41
Approach.....	10.42
Index patient and contact data .....	10.43
Evaluation of a contact investigation.....	10.45

<b>Outbreak Investigation.....</b>	<b>10.47</b>	PATIENT EDUCATION			
Definition of a tuberculosis outbreak.....	10.47	<b>Introduction .....</b>	<b>12.2</b>		
Deoxyribonucleic acid genotyping .....	10.48	Purpose .....	12.2		
<b>Resources and References .....</b>	<b>10.49</b>	Forms .....	12.2		
LABORATORY SERVICES					
<b>Introduction.....</b>	<b>11.2</b>	<b>General Guidelines .....</b>	<b>12.3</b>		
Purpose.....	11.2	<b>Education Topics.....</b>	<b>12.4</b>		
Policy .....	11.2	Language and comprehension barriers.....	12.4		
<b>Laboratory Contact Information.....</b>	<b>11.3</b>	Medical diagnosis.....	12.5		
<b>Available Laboratory Tests.....</b>	<b>11.4</b>	Contact investigation.....	12.5		
<b>Specimen Collection .....</b>	<b>11.7</b>	Isolation.....	12.6		
How to perform spontaneous sputum collection at a healthcare facility .....	11.9	Side effects and adverse reactions .....	12.6		
How to direct a patient to perform spontaneous sputum collection at home.....	11.10	Adherence .....	12.7		
Induced sputum collection at a healthcare facility .....	11.10	<b>Patient Education Materials.....</b>	<b>12.8</b>		
How to collect gastric aspirates .....	11.11	<b>Resources and References.....</b>	<b>12.9</b>		
Bronchoscopy or collection of extrapulmonary specimens.....	11.11	CONFIDENTIALITY			
<b>Specimen Shipment .....</b>	<b>11.12</b>	<b>Introduction .....</b>	<b>13.2</b>		
<b>Resources and References .....</b>	<b>11.14</b>	Purpose .....	13.2		
Centers for Disease Control and Prevention guidance on HIPAA.....	13.3				
Montana HIPAA policies.....	13.4				
<b>National Guidelines .....</b>	<b>13.5</b>				
<b>Resources and References.....</b>	<b>13.6</b>				

<b>TRANSFER NOTIFICATIONS</b>	
<b>Introduction.....</b>	<b>14.2</b>
Purpose.....	14.2
Policy .....	14.2
<b>When to Initiate a Notification .....</b>	<b>14.3</b>
<b>How to Issue a Notification.....</b>	<b>14.4</b>
<b>References .....</b>	<b>14.6</b>

<b>SUPPLIES, MATERIALS, AND SERVICES</b>	
<b>Introduction.....</b>	<b>15.2</b>
<b>Specimen Collection and Shipment Supplies .....</b>	<b>15.3</b>
<b>Tuberculosis Medications for Active and Suspect Cases .....</b>	<b>15.4</b>
<b>Medications for Latent Tuberculosis Infection .....</b>	<b>15.5</b>
<b>Incentives and Enablers.....</b>	<b>15.6</b>
<b>Healthcare Staff Training and Education.....</b>	<b>15.7</b>

## GLOSSARY